Lansoprazole in Preterm Infants With Reflux

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is pilot study to evaluate safety and efficacy of lansoprazole in preterm infants with gastroesophageal reflux documented by 24hr pH impedance monitoring

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

• preterm infant

• documented gastrointestinal reflux by 24hr pH monitoring

Exclusion Criteria:

• unstable vital sings

• congenital anomaly in upper gastrointestinal tract incuding esophagus

• drug history of H2 blocker during last 1 week

• medication of warfarin, carbamazepine, phenytoin, rifampin

• renal or hepatic dysfunction

• inappropriate clinical conditions judged by researchers